Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 20/20 | 0.89 |
| ▸ | EGFR | P00533 | 7/20 | 0.76 |
| ▸ | MET | P08581 | 7/20 | 0.76 |
| ▸ | SRC | P12931 | 7/20 | 0.76 |
| ▸ | PLK4 | O00444 | 2/20 | 0.76 |
| ▸ | AURKA | O14965 | 2/20 | 0.76 |
| ▸ | GAK | O14976 | 2/20 | 0.76 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.76 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.76 |
| ▸ | ERN1 | O75460 | 2/20 | 0.76 |
| ▸ | STK10 | O94804 | 2/20 | 0.76 |
| ▸ | FYN | P06241 | 2/20 | 0.76 |
| ▸ | YES1 | P07947 | 2/20 | 0.76 |
| ▸ | LYN | P07948 | 2/20 | 0.76 |
| ▸ | FER | P16591 | 2/20 | 0.76 |
| ▸ | MARK3 | P27448 | 2/20 | 0.76 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.76 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.76 |
| ▸ | CSK | P41240 | 2/20 | 0.76 |
| ▸ | ABL2 | P42684 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16234538 | 0.94 | AXL (0.89) | AXLEGFRMETSRCPLK4 | |
| SCHEMBL1546563 | 0.94 | AXL (1.00) | AXLEGFRMETSRCPLK4 | |
| SCHEMBL1591619 | 0.93 | AXL (0.86) | AXLEGFRMETSRCPLK4 | |
| SCHEMBL1546932 | 0.92 | AXL (1.00) | AXLEGFRMETSRC | |
| SCHEMBL1547080 | 0.92 | AXL (1.00) | AXLEGFRMETSRCPLK4 | |
| SCHEMBL1546914 | 0.92 | AXL (0.89) | AXLEGFRMETSRCPLK4 | |
| SCHEMBL1547179 | 0.92 | AXL (0.90) | AXLEGFRMETSRCPLK4 | |
| SCHEMBL1546161 | 0.92 | AXL (0.79) | AXLEGFRMETSRCPLK4 | |
| SCHEMBL1591315 | 0.91 | AXL (0.87) | AXLEGFRMETSRCPLK4 | |
| SCHEMBL1546565 | 0.91 | AXL (0.82) | AXLEGFRMETSRCPLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2462117-B1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V (DE) | 2017-06-28 | — | — | EP | claimed |
| US-20140336191-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2014-11-13 | — | — | US | claimed |
| US-20120277231-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2012-11-01 | — | — | US | claimed |
| EP-2462117-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-06-13 | — | — | EP | claimed |
| WO-2011045084-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2011-04-21 | — | — | WO | claimed |
| EP-2311809-A1 | Quinolinyloxyphenylsulfonamides | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2011-04-20 | — | — | EP | claimed |
| EP-2462117-B1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V (DE) | 2017-06-28 | — | — | EP | disclosed |
| EP-2462117-B1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V (DE) | 2017-06-28 | — | — | EP | disclosed |
| US-9169241-B2 | Quinolinyloxyphenylsulfonamides | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2015-10-27 | — | — | US | disclosed |
| US-9169241-B2 | Quinolinyloxyphenylsulfonamides | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2015-10-27 | — | — | US | disclosed |
| US-9169241-B2 | Quinolinyloxyphenylsulfonamides | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2015-10-27 | — | — | US | disclosed |
| US-20140336191-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2014-11-13 | — | — | US | disclosed |
| US-20140336191-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2014-11-13 | — | — | US | disclosed |
| US-20120277231-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2012-11-01 | — | — | US | disclosed |
| US-20120277231-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2012-11-01 | — | — | US | disclosed |
| EP-2462117-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-06-13 | — | — | EP | disclosed |
| WO-2011045084-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011045084-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2011-04-21 | — | — | WO | disclosed |
| EP-2311809-A1 | Quinolinyloxyphenylsulfonamides | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2011-04-20 | — | — | EP | disclosed |
| EP-2311809-A1 | Quinolinyloxyphenylsulfonamides | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2011-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336191-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | TP53, AQP1, KRAS | AXL 4326/4885EGFR 2891/4885MET 2187/4885 |
| US-20120277231-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | TP53, AQP1, KRAS | AXL 4326/4885EGFR 2891/4885MET 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.